<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factors to consider when choosing a PrEP regimen</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factors to consider when choosing a PrEP regimen</h1>
<div class="graphic"><div class="figure"><div class="ttl">Factors to consider when choosing a PrEP regimen</div><div class="cntnt"><table cellspacing="0"><colgroup width="16%"></colgroup><colgroup span="3" width="28%"></colgroup> <tbody> <tr class="border_bottom_thick"> <td class="subtitle1">Â </td> <td class="subtitle1">Benefits</td> <td class="subtitle1">Risks</td> <td class="subtitle1">Additional considerations</td> </tr> <tr class="divider_bottom"> <td><strong>TDF-FTC</strong></td> <td> <ul> <li>Well tolerated.</li> <li>Most studied regimen and can be used in all populations.</li> <li>Can be administered as event-driven therapy for persons who engage only in anal sex (unless they have concurrent chronic HBV infection).</li> </ul> </td> <td> <ul> <li>Can result in reduced kidney function.</li> <li>Can result in bone loss.</li> <li>For patients with chronic HBV, they are at risk for flare of their liver disease if therapy is discontinued.</li> </ul> </td> <td> <ul> <li>TDF should not be used in persons with an eGFR &lt;60.</li> <li>Patients require monitoring of creatinine on therapy.</li> </ul> </td> </tr> <tr class="highlight_gray_text divider_bottom"> <td><strong>TAF-FTC</strong></td> <td> <ul> <li>Well tolerated.</li> <li>Less bone and renal toxicity compared with TDF.</li> </ul> </td> <td> <ul> <li>Should only be administered as daily therapy.</li> <li>Higher rates of mild triglyceride elevations and weight gain compared with TDF-FTC.</li> <li>Should not be used in those whose main risk for HIV is vaginal (frontal) sex or who inject drugs.</li> <li>Less experience compared with TDF, particularly in certain populations (eg, adolescents).</li> <li>For patients with chronic HBV, they are at risk for flare of their liver disease if therapy is discontinued.</li> </ul> </td> <td> <ul> <li>Has not been well studied for PrEP in persons who engage in vaginal (frontal) sex, pregnant persons, or those who inject drugs.</li> <li>There are no data evaluating event-driven dosing in those taking TAF-FTC.</li> </ul> </td> </tr> <tr> <td><strong>Cabotegravir LA</strong></td> <td> <ul> <li>Well tolerated.</li> <li>Administered every other month.</li> <li>Clinical trials suggest efficacy greater than TDF-FTC (possibly related to improved adherence).</li> <li>Can be considered for patients with conditions that are associated with an increased risk of adverse events with TDF-FTC or TAF-FTC (eg, those with reduced kidney function, bone disease)*.</li> </ul> </td> <td> <ul> <li>Cabotegravir LA has a long half-life (drug may be detectable in blood for more than a year). An oral agent (TDF-FTC or TAF-FTC) is required for a period of time when discontinuing cabotegravir LA injections to reduce the risk of developing an integrase inhibitor-resistant strain if HIV infection is acquired when cabotegravir levels are suboptimal*.</li> <li> Future HIV treatment options (ie, use of an integrase strand transfer inhibitor) may be limited if HIV infection occurs and resistance to cabotegravir develops.</li> <li>Need to be near a center that administers cabotegravir LA so doses are not missed.</li> <li>Injection site reactions (generally mild).</li> </ul> </td> <td> <ul> <li>For those who are concerned about side effects of cabotegravir LA, oral cabotegravir (30 mg once daily) can be administered for a 4-week lead-in period prior to initiating injections.</li> <li>There are only limited data in persons who are pregnant or who desire pregnancy.</li> <li>Cabotegravir LA has not yet been studied in persons who inject drugs.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table should be used in conjunction with UpToDate content on pre-exposure prophylaxis.</div><div class="graphic_footnotes"><p>PrEP: pre-exposure prophylaxis; TDF-FTC: tenofovir disoproxil fumarate-emtricitabine; HBV: hepatis B virus; TAF-FTC: tenofovir alafenamide-emtricitabine; LA: long-acting injectable formulation.</p>
* For patients with an absolute contraindication to TDF-FTC or TAF-FTC, consistent condom use or abstinence is required for a period of time if cabotegravir LA is discontinued.</div><div id="graphicVersion">Graphic 140045 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
